FOLH1 and neoplasm: This study demonstrates that combining BET inhibitors with the PSMA-targeted alpha-emitting radioligand [212Pb]Pb-AB001 enhances cytotoxicity in prostate cancer cells, particularly in 3D tumour spheroids.